NI201100100A - Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1. - Google Patents
Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.Info
- Publication number
- NI201100100A NI201100100A NI201100100A NI201100100A NI201100100A NI 201100100 A NI201100100 A NI 201100100A NI 201100100 A NI201100100 A NI 201100100A NI 201100100 A NI201100100 A NI 201100100A NI 201100100 A NI201100100 A NI 201100100A
- Authority
- NI
- Nicaragua
- Prior art keywords
- pharmaceutically acceptable
- positive allosteric
- acceptable salt
- modulators
- aryl methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/19—Acids containing three or more carbon atoms
- C07C53/21—Acids containing three or more carbon atoms containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
El presente invento se refiere a nuevos compuestos de aril metil benzoquinazolinona de la fórmula genérica (I) o una sal farmacéuticamente aceptable de los mismos, que es útil como un modulador alostérico positivo del receptor Ml. El invento se refiere adicionalmente a métodos para tratar un paciente (preferiblemente un ser humano) para enfermedades o trastornos en los que el receptor MI está implicado, tales como enfermedad de Alzheimer, deterioro cognitivo, esquizofrenia, trastornos por dolor y trastornos del sueño, administrando al paciente una cantidad terapéuticamente eficaz de un compuesto de fórmula general (I) o una sal farmacéuticamente aceptable del mismo. El invento también se refiere a composiciones farmacéuticas que incluyen una cantidad eficaz de un compuesto de fórmula (I), o una sal farmacéuticamente aceptable del mismo, y un vehículo farmacéuticamente aceptable, y el uso de los compuestos y composiciones farmacéuticas del invento en el tratamiento de dichas enfermedades.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19974008P | 2008-11-20 | 2008-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201100100A true NI201100100A (es) | 2011-09-12 |
Family
ID=41565956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201100100A NI201100100A (es) | 2008-11-20 | 2011-05-17 | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1. |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US8557832B2 (es) |
| EP (1) | EP2358686B1 (es) |
| JP (1) | JP5102397B2 (es) |
| KR (1) | KR101305590B1 (es) |
| CN (1) | CN102292323B (es) |
| BR (1) | BRPI0921924A2 (es) |
| CA (1) | CA2743562C (es) |
| CO (1) | CO6361928A2 (es) |
| CR (1) | CR20110268A (es) |
| CY (1) | CY1113665T1 (es) |
| DK (1) | DK2358686T3 (es) |
| DO (1) | DOP2011000135A (es) |
| EA (1) | EA019098B1 (es) |
| EC (1) | ECSP11011066A (es) |
| ES (1) | ES2393694T3 (es) |
| GE (1) | GEP20156348B (es) |
| GT (1) | GT201100127A (es) |
| HK (1) | HK1154587A1 (es) |
| HN (1) | HN2011001358A (es) |
| HR (1) | HRP20120992T1 (es) |
| IL (1) | IL212573A (es) |
| MA (1) | MA32898B1 (es) |
| MX (1) | MX2011005284A (es) |
| MY (1) | MY162502A (es) |
| NI (1) | NI201100100A (es) |
| NZ (1) | NZ592961A (es) |
| PE (1) | PE20120031A1 (es) |
| PL (1) | PL2358686T3 (es) |
| PT (1) | PT2358686E (es) |
| RS (1) | RS52528B (es) |
| SG (1) | SG171769A1 (es) |
| SI (1) | SI2358686T1 (es) |
| SV (1) | SV2011003912A (es) |
| TN (1) | TN2011000209A1 (es) |
| UA (1) | UA100459C2 (es) |
| WO (1) | WO2010059773A1 (es) |
| ZA (1) | ZA201103612B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012003464B8 (pt) * | 2009-08-31 | 2021-05-25 | Merck Sharp & Dohme | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica |
| EP2490692B1 (en) | 2009-10-21 | 2016-11-16 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| EP2512245B1 (en) * | 2009-12-14 | 2014-07-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
| US9199939B2 (en) | 2009-12-17 | 2015-12-01 | Merck Sharp & Dohme Corp. | Quinoline amide M1 receptor positive allosteric modulators |
| US8383638B2 (en) * | 2009-12-21 | 2013-02-26 | Merck Sharp & Dohme | Aminobenzoquinazolinone M1 receptor positive allosteric modulators |
| WO2011159553A1 (en) * | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
| EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| US8664234B2 (en) * | 2010-10-04 | 2014-03-04 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators |
| WO2012158473A1 (en) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators |
| AR088786A1 (es) | 2011-08-12 | 2014-07-10 | Basf Se | Compuestos de antranilamida y sus usos como plaguicidas |
| EP2742022A1 (en) | 2011-08-12 | 2014-06-18 | Basf Se | Anthranilamide compounds and their use as pesticides |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| IN2012DE00083A (es) * | 2012-01-10 | 2015-05-01 | Council Scient Ind Res | |
| US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
| US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| DE112015001835T5 (de) | 2014-04-17 | 2016-12-29 | Sumitomo Chemical Company, Limited | Verfahren zur Herstellung einer Nitroverbindung |
| WO2016144727A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
| EP3313836B1 (en) * | 2015-06-26 | 2020-11-11 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| CA2996717A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| WO2017058691A1 (en) * | 2015-09-30 | 2017-04-06 | Merck Sharp & Dohme Corp. | Process for making m1 receptor positive allosteric modulators |
| EP3356333A4 (en) * | 2015-09-30 | 2019-03-27 | Merck Sharp & Dohme Corp. | CRYSTAL FORMS OF AN M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR |
| US10548899B2 (en) * | 2015-10-20 | 2020-02-04 | Takeda Pharmaceutical Company Limited | Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity |
| AU2017251537B2 (en) | 2016-04-15 | 2020-10-08 | Abbvie Inc. | Bromodomain inhibitors |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| UA125628C2 (uk) | 2016-10-14 | 2022-05-04 | Пі Індастріз Лтд | Похідні 4-заміщеного феніламіну і їх використання для захисту культур від небажаних фітопатогенних мікроорганізмів |
| EP3535253A1 (en) | 2016-11-01 | 2019-09-11 | H. Hoffnabb-La Roche Ag | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of cns related diseases |
| WO2018212312A1 (ja) | 2017-05-19 | 2018-11-22 | 武田薬品工業株式会社 | スクリーニング方法 |
| KR20210068025A (ko) | 2018-09-28 | 2021-06-08 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로시클릭 화합물 |
| EP4308664A1 (de) | 2021-03-18 | 2024-01-24 | Merck Patent GmbH | Heteroaromatische verbindungen für organische elektrolumineszenzvorrichtungen |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2180798T3 (es) * | 1995-10-02 | 2003-02-16 | Hoffmann La Roche | Derivados de pirimidina como antagonistas del receptor de 5ht2c. |
| JP2001507349A (ja) * | 1996-12-23 | 2001-06-05 | セルテック セラピューティックス リミテッド | 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用 |
| JP4484368B2 (ja) * | 1998-10-16 | 2010-06-16 | 大日本住友製薬株式会社 | キナゾリノン誘導体 |
| JP2005089298A (ja) * | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
| US20060233843A1 (en) | 2003-02-19 | 2006-10-19 | Conn P J | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| MX2007013606A (es) * | 2005-05-04 | 2007-12-10 | Hoffmann La Roche | (3,4-dihidro-quinazolin2-il)-(2-ariloxi-etil)-aminas que tienen una actividad en el receptor 5-ht. |
| CA2655787A1 (en) * | 2006-06-28 | 2008-01-03 | Merck And Co., Inc. | Benzyl-substituted quinolone m1 receptor positive allosteric modulators |
| US8664234B2 (en) * | 2010-10-04 | 2014-03-04 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators |
-
2009
- 2009-11-19 CN CN200980155011.4A patent/CN102292323B/zh active Active
- 2009-11-19 MX MX2011005284A patent/MX2011005284A/es active IP Right Grant
- 2009-11-19 MY MYPI2011002215A patent/MY162502A/en unknown
- 2009-11-19 EP EP09761104A patent/EP2358686B1/en active Active
- 2009-11-19 ES ES09761104T patent/ES2393694T3/es active Active
- 2009-11-19 RS RS20120522A patent/RS52528B/en unknown
- 2009-11-19 GE GEAP200912265A patent/GEP20156348B/en unknown
- 2009-11-19 PL PL09761104T patent/PL2358686T3/pl unknown
- 2009-11-19 WO PCT/US2009/065060 patent/WO2010059773A1/en active Application Filing
- 2009-11-19 DK DK09761104.0T patent/DK2358686T3/da active
- 2009-11-19 BR BRPI0921924A patent/BRPI0921924A2/pt active Search and Examination
- 2009-11-19 JP JP2011537601A patent/JP5102397B2/ja active Active
- 2009-11-19 NZ NZ592961A patent/NZ592961A/xx not_active IP Right Cessation
- 2009-11-19 UA UAA201107595A patent/UA100459C2/ru unknown
- 2009-11-19 PT PT97611040T patent/PT2358686E/pt unknown
- 2009-11-19 US US13/129,593 patent/US8557832B2/en active Active
- 2009-11-19 EA EA201170705A patent/EA019098B1/ru not_active IP Right Cessation
- 2009-11-19 CA CA2743562A patent/CA2743562C/en active Active
- 2009-11-19 SG SG2011036472A patent/SG171769A1/en unknown
- 2009-11-19 KR KR1020117011415A patent/KR101305590B1/ko active IP Right Grant
- 2009-11-19 PE PE2011001058A patent/PE20120031A1/es not_active Application Discontinuation
- 2009-11-19 SI SI200930460T patent/SI2358686T1/sl unknown
-
2011
- 2011-04-28 IL IL212573A patent/IL212573A/en not_active IP Right Cessation
- 2011-04-29 TN TN2011000209A patent/TN2011000209A1/fr unknown
- 2011-05-12 DO DO2011000135A patent/DOP2011000135A/es unknown
- 2011-05-17 GT GT201100127A patent/GT201100127A/es unknown
- 2011-05-17 NI NI201100100A patent/NI201100100A/es unknown
- 2011-05-17 ZA ZA2011/03612A patent/ZA201103612B/en unknown
- 2011-05-19 HN HN2011001358A patent/HN2011001358A/es unknown
- 2011-05-20 EC EC2011011066A patent/ECSP11011066A/es unknown
- 2011-05-20 SV SV2011003912A patent/SV2011003912A/es unknown
- 2011-05-20 CR CR20110268A patent/CR20110268A/es unknown
- 2011-05-24 CO CO11063884A patent/CO6361928A2/es active IP Right Grant
- 2011-06-13 MA MA33939A patent/MA32898B1/fr unknown
- 2011-08-25 HK HK11108976.8A patent/HK1154587A1/xx not_active IP Right Cessation
-
2012
- 2012-12-03 HR HRP20120992AT patent/HRP20120992T1/hr unknown
- 2012-12-17 CY CY20121101227T patent/CY1113665T1/el unknown
-
2013
- 2013-08-29 US US14/013,184 patent/US8883810B2/en active Active
-
2014
- 2014-10-08 US US14/509,580 patent/US20150031713A1/en not_active Abandoned
-
2015
- 2015-08-17 US US14/828,216 patent/US9708273B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201100100A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1. | |
| MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
| CO6551729A2 (es) | Moduladores alostericos positivos de receptores de m1 de quinolina amida | |
| CO6270360A2 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
| EA201171197A8 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| CO6501188A2 (es) | Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1 | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| EP2037739A4 (en) | POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| RS52583B (en) | TREATMENT OF COGNITIVE DISORDERS WITH (R) -7-CHLORO-N- (HINUCLIDIN-3-IL) BENZO [B] THIOPHENE-2-CARBOXAMIDE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | |
| MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| DOP2019000076A (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO | |
| CO6341624A2 (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
| UY29823A1 (es) | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| MA32719B1 (fr) | Formulations galeniques de composes organiques | |
| WO2009117283A3 (en) | Quinolizidinone m1 receptor positive allosteric modulators |